Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Imfinzi |
Active Ingredient: | Durvalumab 120mg |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | AstraZeneca Limited |
Manufacturers: | Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany AstraZeneca AB, Sodertalje, Sweden Catalent Indiana LLC, Indiana, United States of America |
Product: | Imfinzi |
Active Ingredient: | Durvalumab 500mg |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | AstraZeneca Limited |
Manufacturers: | Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany AstraZeneca AB, Sodertalje, Sweden Catalent Indiana LLC, Indiana, United States of America |
Dated this 27th day of January 2023.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).